Voxtalisib (SAR245409, XL765) is a dual inhibitor of mTOR/PI3K, mostly for p110γ with IC50 of 9 nM; also inhibits DNA-PK and mTOR. Phase 1/2.
Voxtalisib (SAR245409, XL765) is a dual inhibitor of mTOR/PI3K, mostly for p110γ with IC50 of 9 nM; also inhibits DNA-PK and mTOR. Phase 1/2.
Voxtalisib (SAR245409, XL765) is a dual inhibitor of mTOR/PI3K, mostly for p110γ with IC50 of 9 nM; also inhibits DNA-PK and mTOR. Phase 1/2.
PI3K-IN-1 (XL-147 derivative 1) is a dual inhibitor of mTOR/PI3K, mostly for p110γ with IC50 of 9 nM; also inhibits DNA-PK and mTOR. Phase 1/2.
PI3K-IN-1 (XL-147 derivative 1) is a dual inhibitor of mTOR/PI3K, mostly for p110γ with IC50 of 9 nM; also inhibits DNA-PK and mTOR. Phase 1/2.
PI3K-IN-1 (XL-147 derivative 1) is a dual inhibitor of mTOR/PI3K, mostly for p110γ with IC50 of 9 nM; also inhibits DNA-PK and mTOR. Phase 1/2.
PI3K-IN-1 (XL-147 derivative 1) is a dual inhibitor of mTOR/PI3K, mostly for p110γ with IC50 of 9 nM; also inhibits DNA-PK and mTOR. Phase 1/2.
VPC-14228 is a potent and specific inhibitor of human androgen receptor (AR) that binds to AR DNA-binding domain (AR DBD).
VPC-14228 is a potent and specific inhibitor of human androgen receptor (AR) that binds to AR DNA-binding domain (AR DBD).
VPC-14228 is a potent and specific inhibitor of human androgen receptor (AR) that binds to AR DNA-binding domain (AR DBD).
VPC-14228 is a potent and specific inhibitor of human androgen receptor (AR) that binds to AR DNA-binding domain (AR DBD).
VPC-14228 is a potent and specific inhibitor of human androgen receptor (AR) that binds to AR DNA-binding domain (AR DBD).